Pharma Pricing Congress

Hot topics in pharma and orphan drugs

By Christina Poschen I attended this year’s Pharma Pricing and Market Access Conference in London with attendees across the pharmaceutical industry, payer and HTA bodies and patient representatives. While following the talks, panel discussions and roundtable debates, a few overarching key topics crystallised: –          Germany – AMNOG changes AMNOG, the German pharmaceutical law is regularly adapted to changes in the …

Essential payer insights

Using real world evidence in clinical trials is critical to the success of patient recruitment and payer engagement programs. Through more stakeholder collaboration, we can help patients access the right treatment for them. How can we achieve this in practice? How do we overcome pricing and funding challenges? How can we use data better? We put these important questions to …

The Netherlands: In the midst of change

  At the World Pharma Pricing & Market Access Congress 2014 conference, Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ gave the presentation: “The Netherlands: In the mi(d)st of change” Download and learn: Organisational change in CVZ End of an era: Policy rules and outcomes research First results and experiences with CED Preliminary criteria for prioritizing inpatient drugs Priorities Are …

Italy, Update, Reform, Agenda, Pharma Pricing

Italy: update on the reform agenda

At World Pharma Pricing & Market Access Congress 2014, Dr Giovanni Tafuri, AIFA, gave a presentation on  “Italy: update on the reform agenda” Tafuri’s presentation discusses his thoughts on how to solve current problems like how to balance fast market access with available resources, how to harmonize market access across regions, and  how to cope with uncertainty when deciding on pricing …

pharma, pharma pricing, market access, drug, considerations, pharma pricing and market access europe

Ebook: Key Considerations for Market Access

In an era of austerity and rising health care costs, payers are exerting greater influence over pharmaceutical markets and demanding insight into a drug’s value and cost effectiveness. Creating an effective market access strategy is vital for a successful product launch. You need to integrate the payer perspective throughout the development and decisions making process. In this ebook, we share …

Netherlands, Anticipate, Future, Pharma, Pharma Pricing

The Netherlands: How to anticipate future pharma and healthcare dynamics?

At the World Pharma Pricing and Market Access Congress 2014, Cornelis Boersma, Head Market Access GSK, gave a presentation “The Netherlands: How to anticipate future pharma and healthcare dynamics?” Boersma’s presentation reflects his attitude “Change towards a predictable and sustainable decision-making system!” Download and learn: Trends in healthcare and pharma expenditures Dutch Pharma system under development NL policy: Implementation of ‘Vuvuzela’ Market Access and …

HTA, France, Update, Pharma Pricing

Update on the New HTA in France

At the World Pharma Pricing & Market Access Congress 2014,  Jean-Luc Harousseau, President, HAS, gave a presentation entitled  “Updates on the New HTA in France” Download the presentation to learn: HTA in France :  Reimbursement and Pricing Initial listing: From HAS guidance to CEPS pricing Actual benefit (SMR): reimbursement and co-payment level Clinical Added Value (ASMR) 2008 –2012 Prices of new …

Download: Top tips and takeaways from Pharma Pricing & Market Access Outlook Europe

  Currently in its 9th year, World Pharma Pricing & Market Access Congress is the world’s best received and attended pharma market access meeting. With an unprecedented number of support from the international payer community, the event was able to provide valuable advice, insight and solutions to help pharma achieve market access in the major European markets. Leading healthcare professionals and …

value, assessment

Value based assessment: NICE’s role

At Pharma Pricing & Market Access Europe 2014, David Haslam, Chairman, NICE, gave a presentation on “Value based assessment: NICE’s role” Haslam’s presentation discussed  incorporating burden of illness and wider societal impact into NICE’s technology assessment methods. Download and learn: Value Based Assessment NICE’s current approach Costs and benefits New DH terms of reference Approaches to appraising the impact of technologies …